Bitop AG, a biotech company specializing in the evolvement of Ectoin®-containing medical devices, reports that Ectoin allergy nasal spray has been shown to significantly reduce disorder of acute immune sensitive rhinitis in a two-week observational, randomized, comparative crossover study with 50 vocation hardship from acute affected rhinitis. Based on this study, bitop performed a clinical trial on eyes drops and nasal spray in humans using an environmental control third edition by the editors of the american heritage dictionary. copyright 2003 chamber (EEC) model.

More: - Brought to my attention by